References
- Nana A ,Gruessner A, Agopian VG, et al. Survival benefit of
solid-organ transplant in the United States. JAMA Surg.
2015;150:252-259.
- Lamb KE, Lodhi S, Meier-Kriesche H-U. Long-term renal allograft
survival in the United States: a critical reappraisal. Am J
Transplant. 2011;11:450-462.
- Hart A, Smith JM, Skeans MA, Gustafson SK, et al. OPTN/SRTR 2017
Annual Data Report: Kidney. Am J Transplant. 2019;19 (Suppl 2):19-123.
- Nankivell BJ, Chapman JR. The significance of subclinical rejection
and the value of protocol biopsies. Am J Transplant 2006;6:2006e12.
- Kuypers DR. Immunosuppressive drug therapy and subclinical acute renal
allograft rejection: impact and effect. Transplantation. 2008;85
(Suppl 7):S25-30.
- Loupy A, Vernerey D, Tinel C, et al. Subclinical rejection phenotypes
at 1 year post-transplant and outcome of kidney allografts. Am J Soc
Nephrol 2015;26:1721e31.
- Friedewald JJ, Kurian SM, Heilman RL, et al. Development and clinical
validity of a novel blood‐based molecular biomarker for sub‐clinical
acute rejection following kidney transplant. Am J Transplant
2019;19:98‐109.
- Hoffman W, Mehta R, Jorgensen DR, et al. The impact of early clinical
and subclinical T cell-mediated rejection after kidney
transplantation. Transplantation 2019; 103:1457-1467.
- Waldmann H. Drug minimization in transplantation. Curr Opin Organ
Transplant 2014; 19:331-333.
- Metha R, Cherikh W, Sood P, Hariharan S. Kidney allograft surveillance
biopsy practices across US transplant centers: A UNOS survey. Clin
Transplant 2017; DOI: 10.1111/ctr.12945.
- Lee DM, Abecassis MM, Friedewald JJ, Rose S, First MR. Kidney Graft
Surveillance Biopsy Utilization and Trends – Results from a Survey of
High Volume Transplant Centers (Abstract, American Transplant
Congress, Boston, MA, 2019.)
- Mengel M, Sis B, Halloran PF (2007) SWOT analysis of Banff: strengths,
weaknesses, opportunities and threats of the international Banff
consensus process and classification system for renal allograft
pathology. Am J Transplant 7:2221-2226.
- Morgan TA, Chandran S, Burger IM, Zhang CA, Goldstein RB.
Complications of ultrasound-guided renal transplant biopsies. Am J
Transplant 2016;16:1298e305.
- Haas M, Loupy A, Lefaucheur C et al. The Banff 2017 Kidney Meeting
Report: Revised diagnostic criteria for chronic active T
cell–mediated rejection, antibody- mediated rejection, and prospects
for integrative endpoints for next- generation clinical trials. Am J
Transplant 2017; DOI:10.1111/ajt.14625.
- Heilman R,Taber D, Guo K, et al.,Early subclinical rejection by biopsy
or gene expression profile predicts long-term kidney function in
patients in the CTOT 08 trial (Abstract, American Transplant Congress,
Boston, MA, 2019.)
- Mehta R, Bhusal S, Randhawa P, et al. Short-term adverse effects of
early subclinical allograft inflammation in kidney transplant
recipients with a rapid steroid withdrawal protocol. Am J Transplant
2018;18:1710-1717.
- Nankivell BJ, Agrawal N, Sharma A, et al. The clinical and
pathological significance of borderline T cell mediated rejection. Am
J Transplant. 2018; DOI: 10.1111/ajt.15197.
- Seifert ME, Yanik MV, Feig DI, et al. Subclinical inflammation
phenotypes and long-term outcomes after pediatric kidney
transplantation. Am J Transplant. 2018;18: 2189-2199.
- Zhang W, Yi Z, Wei C, et al. Pretransplant transcriptomic signature in
peripheral blood predicts early acute rejection. JCI Insight.
2019;4(11):e127543. https://doi.org/10.1172/jci.insight.127543.
- First MR, Pierry D, McNulty M, et al. Analytical and clinical
validation of a molecular diagnostic signature in kidney transplant
recipients. J Transplant Technol Res 7: 3. 2017; doi:
10.4172/2161-0991.1000176.
- First MR, Whisenant T, Friedewald JJ, et al. Clinical utility of
peripheral blood gene expression profiling of kidney transplant
recipients to assess the need for surveillance biopsies in subjects
with stable renal function. J Transplant Technol Res 7: 3. 2017; doi:
10.4172/2161-0991.1000177.
- Marsh CL, Kurian SM, Rice JC, Whisenant TC, et al. Application of
TruGraf v1: A novel molecular biomarker for managing kidney transplant
recipients with stable renal function. Transplant Proc.
2019;51:722-728.
- First MR, Peddi VR, Mannon R, et al. Investigator assessment of the
utility of the TruGraf molecular diagnostic test in clinical practice.
Transplant Proc. 2019;51:729-733.
- Friedewald J, Abecassis M. Clinical implications for the use of a
biomarker for subclinical rejection - Conflating arguments cause a
disconnection between the premise and the conclusion. Am J Transplant.
2019;19(7): 2141-2142.